On Friday, Apogee Therapeutics cleared a noteworthy technical benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 84, up from 73 the day before.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the best stocks typically have an 80 or better RS Rating in the early stages of their moves.
Apogee Therapeutics has moved more than 5% past a 47.71 entry in a first-stage cup without handle, meaning it's now out of a proper buy range. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% EPS growth in its most recent report. Revenue gains came in at 0%.
The company earns the No. 341 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Incyte and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
